At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 45 enrolled
Drug / intervention
Florbetaben (BAY94-9172)drug
Likely dose
Florbetaben (BAY94-9172) 2 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
ß-amyloid Imaging With BAY94-9172 Positron Emission Tomography for Early Detection of Alzheimer's Disease in Patients With Mild Cognitive Impairment
In Brief
A Phase 1 clinical trial evaluating Florbetaben (BAY94-9172) for Alzheimer Disease and Amyloid Beta-Protein. Completed, enrolled 45 participants across 1 site.
Detailed Summary
The aim of the study is to investigate whether Florbetaben (BAY94-9172)positron emission tomography (PET) is able to distinguish between subjects with mild cognitive impairment (MCI) progressing to Alzheimer's disease (AD) from those with MCI not progressing to AD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease, Amyloid Beta-Protein
CountriesAustralia
Collaborators--
Timeline
Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2008
First PostedJun 2010
Primary CompletionDec 2011
TodayJul 2026
First PostedJun 7, 2010
Enrollment StartJun 1, 2008
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 16.1 years ago
Interventions
Florbetaben (BAY94-9172)drug
single 300 megabecquerel (MBq) intravenous injection 2 mL to 10 mL, at baseline, at 12 and 24 months